Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T9159 |
PBT-1033
PB 1033,PBT1033,PBT-2,PBT 2,PBT2 |
Others | Others |
PBT-1033 (PBT-2) 是一种潜在的神经保护剂,用于治疗阿尔茨海默病和亨廷顿病。 | |||
T1764 |
Adezmapimod
PB 203580,4-(4-氟苯基)-2-(4-甲基亚磺酰基苯基)-5-(4-吡啶基)-1H-咪唑,RWJ 64809,SB203580 |
Mitophagy; p38 MAPK; Autophagy | Autophagy; MAPK |
Adezmapimod (SB 203580) 是一种 p38 MAPK 抑制剂 (IC50=0.3-0.5 μM),具有选择性和 ATP 竞争性。Adezmapimod 具有自噬和线粒体自噬的激活活性。Adezmapimod 显示出比 PKB、LCK 和 GSK-3β 高 100 倍以上的选择性。 | |||
T35889 |
PB2
|
||
PB2, a tris(2-carboxyethyl)phosphine (TCEP) analogue, enhances the survival of retinal ganglion cells (RGCs) following axotomy in vitro. Even at nanomolar and picomolar concentrations, PB2 demonstrates pronounced efficacy in promoting RGC survival. Notably, PB2 exhibits superior permeability compared to TCEP. Serving as a potent reducing agent, PB2 provides robust neuroprotection for RGCs[1]. | |||
T36679 |
Rp-cAMPS sodium salt
|
||
Rp-cAMPS sodium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (Kis of 12.5 μM and 4.5 μM, respectively) antagonist. Rp-cAMPS sodium salt is resistant to hydrolysis by phosphodiesterases[1][2][3][4][5][6]. A membrane-permeable competitive cAMP antagonist (Rp-cAMPS) that blocks PKA activation by binding to the regulatory subunits without dissociating the kinase holoenzyme also inhibits synaptic plasticity but has no effect on normal synaptic t... |